e-Therapeutics at a Glance
e-Therapeutics is pioneering the new science of network pharmacology in drug discovery. Scientists at the Company's Network Pharmacology Centre near Oxford are seeking novel treatments for cancer and degenerative diseases of the nervous system. The company has advanced two drugs into clinical trial - one for cancer and one for major depressive disorder. e-Therapeutics has a site in Newcastle-upon-Tyne in addition to its new centre near Oxford. The Company is listed on the AIM market of the London Stock Exchange (ticker ETX).
Listing and Share Price
e-Therapeutics is listed on the AIM market of the London Stock Exchange under the ticker symbol ETX.
For latest news click here and for a full list of all announcements, click here.
JPMorgan conference, San Francisco, USA, 13-15 January 2014
Presentations and Reports
Access our latest corporate presentation and financial reports.
- Invesco - 131,331,539 (49.8%)
- Aviva - 42,750,000 (16.2%)
- Malcolm Young - 20,644,958 (7.8%)
- Henderson Global Investors - 17,539,408 (6.7%)
- Octopus Group – 11,097,658 (4.2%)
The total number of ordinary shares in issue as of 6 August 2013 (most recent issue of new shares) was 263,766,443.
The following analysts cover e-Therapeutics:
- Savvas Neophytou, Panmure Gordon
- Franc Gregori, Edison*
- Emanuil Halicioglu, Growth Equities & Company Research*
*Designates that research is ‘paid-for’ coverage produced under a contract with e-Therapeutics
The following link has details of the Company’s Nominated Adviser and other key advisers: Advisers
For investor relations enquiries and holdings notifications:
Daniel Elger, CFO
For questions concerning share certificates or changes of shareholder address or other details, please contact Neville Registars:
Neville Registrars Limited
18 Laurel Lane
Tel: +44 (0) 121 585 1131
Fax: +44 (0) 121 585 1132
Investor Relations and governance pages last updated 06 August 2013